Marco Winzer

Marco Winzer

Marco Winzer has been with High-Tech Gründerfonds since its foundation and has helped to establish the fund. The economics graduate has many years of experience in financing start-ups in the life sciences industry and has supported a number of start-ups all along the value chain of the ‘Venture Capital Model’ – from seed financing to successful exit. Before working for HTGF, the Partner acquired expertise in consulting start-ups and held various positions at the Business Innovation Center Kaiserslautern as well as the Technologie-Beteiligungsgesellschaft and development bank KfW.

Contact

Telefon:
+49 – (0)228 – 82300 – 106

Portfolio

Posts & mentions

23. June 2021

Successful Exit for Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW – PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

SIRION Biotech, Martinsried near Munich, will continue to grow its leading position in viral vector technologies for cell and gene therapy as part of PerkinElmerThe addition of SIRION’s offerings will complement PerkinElmer’s Horizon Discovery portfolioIn 2007 High-Tech Gründerfonds, Creathor Ventures together with KfW and Bayern Kapital were the first seed investors of SIRION Biotech GmbHThe transaction is subject to regulatory approvals Bonn, 23.06.2021 – High-Tech Gründerfonds,
 
22. April 2021

High-tech and humanity - robotic assistance enters intensive care units

Intelligent, assistive robotics for early mobilization of critically illintensive care patients convinces investors. Fighting the shortage of nurses with cutting-edge technology. Supporting nurses, accelerating recovery. Reactive Robotics employs its robotic assistance system to treat, among others, Covid-19 patients in intensive care units, to enable these patients in recovering faster. The company has now raised a mid-seven-figure sum in a financing round. In addition to the existing
 
25. January 2021

i3 Membrane receives 7 figure sum for development and market launch of new separation technology for biomolecules

Four investors are financing the further growth of i3 Membrane GmbH. High-tech venture capital investor HTGF from Bonn, Germany, and three private investors are together investing a 7 figure sum in the further development and market launch of new separation technology for biological molecules. The centerpiece for this round of financing is the construction of the company's own production facility for membrane filters in Radeberg near Desden. The new separation technology is to be made ready
 
13. November 2020

High-Tech Gründerfonds: Successful sale of portfolio company m2p-labs GmbH to Beckman Coulter Life Sciences

Together with lead investor FIDURA, KfW Development Bank, TechVision Fonds and other co-investors, High-Tech Gründerfonds (HTGF) has successfully sold its shares in m2p-labs GmbH, one of the leading manufacturers of microbioreactors, to Beckman Coulter Life Sciences. Founded in 2005, m2p-labs is a leading global manufacturer of microbioreactors.  „m2p“stands for „from microreactor to process“. Using optical measuring technology and microfluidic chip technology combined with min
 
Blog
8. July 2020

"You don't need entrepreneurship in your genes to successfully found a life sciences company"

HTGF Partner Marco Winzer has been with High-Tech Gründerfonds since its foundation. In an interview, he talks about why real entrepreneurship is not something you can learn in the classroom. However, he also advises anyone with an innovative idea to make sure they found a company themselves and outlines what they need to do to make this happen. Marco, do successful founders usually have business degrees? Or do they tend to be inventors, programmers and scientists? Marco Winzer: P